(NASDAQ: PTCT) Ptc Therapeutics's forecast annual revenue growth rate of -6.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.21%.
Ptc Therapeutics's revenue in 2026 is $1,730,655,000.On average, 16 Wall Street analysts forecast PTCT's revenue for 2026 to be $84,181,900,410, with the lowest PTCT revenue forecast at $57,537,542,570, and the highest PTCT revenue forecast at $122,672,149,860. On average, 16 Wall Street analysts forecast PTCT's revenue for 2027 to be $99,081,351,810, with the lowest PTCT revenue forecast at $63,743,164,078, and the highest PTCT revenue forecast at $167,453,278,790.
In 2028, PTCT is forecast to generate $118,036,764,980 in revenue, with the lowest revenue forecast at $63,941,823,430 and the highest revenue forecast at $204,536,357,830.